Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. (Q36184218)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15998418%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

review article

1 reference

title

Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15998418%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

main subject

hepatocellular carcinoma

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15998418%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

Ding-Shinn Chen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15998418%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

author name string

Jia-Horng Kao

series ordinal

1

1 reference

12 August 2017

1 August 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15998418%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15998418%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15998418%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15998418%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

page(s)

696-703

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15998418%20AND%20SRC:MED&resulttype=core&format=json

International trends and patterns of primary liver cancer.

13 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Global control of hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Characteristics of hepatocellular carcinoma in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Varied assembly and RNA editing efficiencies between genotypes I and II hepatitis D virus and their implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Transmission of hepatitis C virus in Asia: past and present perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Hepatitis C virus antibodies among risk groups in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Hepatocellular carcinoma. A worldwide problem and the major risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01139.X

10.1111/J.1478-3231.2005.01139.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15998418%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

1 reference